ArticleImmunoTargets and therapy2025
Soluble Programmed Cell Death-1: A Potential Predictor of HBsAg Loss in Pediatric Patients with Chronic Hepatitis B Undergoing Peginterferon Therapy.
Article in ImmunoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Soluble programmed cell death-1 (sPD-1) level can predict hepatitis B surface antigen (HBsAg) loss in adult chronic hepatitis B (CHB) patients. However, whether sPD-1 level can serve as a potential seromarker for predicting HBsAg loss in pediatric patients remained to determine. Patients and Methods: Ninety-two pediatric HBeAg-positive CHB patients who received peginterferon (PegIFN) therapy with available serum samples were studied retrospectively. The average follow-up time was 45.0 months. Virological biomarkers and sPD-1 were serially measured. Results: A total of 45 (48.9%) children achieved HBsAg loss at the end of treatment (EOT), and 84.4% (38/45) of them remained HBsAg-negative at the end of follow-up. At baseline, sPD-1 levels were comparable between patients who subsequently achieved HBsAg loss and those who did not ( Conclusion: Early on-treatment serum sPD-1 level has a potential predictive value for HBsAg loss in pediatric patients with HBeAg-positive CHB, which might provide a clue to optimize the management of PegIFN therapy. However, a prospective, multi-center study is warranted for further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.